Zell S C, Goodman P H
West J Med. 1988 May;148(5):541-5.
We randomly assigned 32 healthy backpackers to receive placebo, acetazolamide (250 mg twice a day), dexamethasone acetate (4 mg four times a day), or both drugs in combination to determine the drug efficacy in preventing acute mountain sickness (AMS) at altitudes of 3,650 to 4,050m (12,000 to 13,300 ft). The incidence of AMS was high but symptoms were generally mild. Combined drug therapy was superior to both placebo and single drug therapy in risk reduction. Using acetazolamide alone was moderately beneficial in preventing the occurrence of AMS, although minor side effects were frequent. The use of dexamethasone alone did not significantly reduce the AMS incidence, and discontinuing its use resulted in symptoms suggestive of adrenal insufficiency. For recreational backpackers, routine drug prophylaxis is not recommended, in view of the mild nature of this illness and the adverse effects of medications. The efficacy of combined acetazolamide-dexamethasone therapy warrants further investigation at higher altitudes, where AMS is more severe, and the dexamethasone should be withdrawn gradually to avoid a possible adrenal crisis.
我们随机分配32名健康背包客,让他们分别服用安慰剂、乙酰唑胺(每日两次,每次250毫克)、醋酸地塞米松(每日四次,每次4毫克)或两种药物的组合,以确定这些药物在海拔3650至4050米(12000至13300英尺)预防急性高原病(AMS)的疗效。AMS的发病率很高,但症状通常较轻。联合药物治疗在降低风险方面优于安慰剂和单一药物治疗。单独使用乙酰唑胺对预防AMS的发生有一定益处,尽管轻微副作用较为常见。单独使用地塞米松并未显著降低AMS的发病率,停用后会出现提示肾上腺功能不全的症状。对于休闲背包客,鉴于该病症状较轻且药物有不良反应,不建议进行常规药物预防。乙酰唑胺 - 地塞米松联合治疗的疗效在更高海拔地区(AMS更严重)值得进一步研究,且地塞米松应逐渐停药以避免可能的肾上腺危机。